tiprankstipranks
Arbutus Biopharma (GB:0SGC)
NASDAQ:0SGC
UK Market

Arbutus Biopharma (0SGC) Share Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

0SGC Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Arbutus
Biopharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0SGC Stock 12 Month Forecast

There Are No Analyst Ratings for GB:0SGC In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

0SGC Financial Forecast

0SGC Earnings Forecast

Next quarter’s earnings estimate for 0SGC is -$0.02 with a range of -$0.02 to -$0.02. The previous quarter’s EPS was -$0.03. 0SGC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0SGC has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0SGC is -$0.02 with a range of -$0.02 to -$0.02. The previous quarter’s EPS was -$0.03. 0SGC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0SGC has Performed in-line its overall industry.

0SGC Sales Forecast

Next quarter’s sales forecast for 0SGC is $1.00M with a range of $1.00M to $1.00M. The previous quarter’s sales results were $1.01M. 0SGC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0SGC has Performed in-line its overall industry.
Next quarter’s sales forecast for 0SGC is $1.00M with a range of $1.00M to $1.00M. The previous quarter’s sales results were $1.01M. 0SGC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0SGC has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on GB:0SGC
Jefferies
Jefferies
$7
Buy
110.84%
Upside
Reiterated
12/11/25
We've written extensively about the cases (primer here). A positive outcome with MRNA would also de-risk the PFE case, which is slightly behind, and which has a larger revenue pool associated with it. judgment will be another catalyst in the near term. judgment and Daubert briefings have just wrapped up.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on GB:0SGC
Jefferies
Jefferies
$7
Buy
110.84%
Upside
Reiterated
12/11/25
We've written extensively about the cases (primer here). A positive outcome with MRNA would also de-risk the PFE case, which is slightly behind, and which has a larger revenue pool associated with it. judgment will be another catalyst in the near term. judgment and Daubert briefings have just wrapped up.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
AXGNAxoGen
ATECAlphatec Holdings
CABACabaletta Bio
ONCBeOne Medicines
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arbutus Biopharma

3 Months
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
2/2 ratings generated profit
100%
Average Return
+6.85%
Copying PerPlexity Biotechnology's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +6.85% per trade.
1 Year
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
2/2 ratings generated profit
100%
Average Return
+7.30%
Copying PerPlexity Biotechnology's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +7.30% per trade.
2 Years
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
2/2 ratings generated profit
100%
Average Return
+7.30%
Copying PerPlexity Biotechnology's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +7.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0SGC Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
0
0
In the current month, 0SGC has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0SGC average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

0SGC Stock Forecast FAQ

What is GB:0SGC’s average 12-month price target, according to analysts?
Currently, no data Available
What is GB:0SGC’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for GB:0SGC, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Arbutus Biopharma a Buy, Sell or Hold?
      Currently, no data Available
      What is Arbutus Biopharma’s share price target?
      Currently, no data Available
      What do analysts say about Arbutus Biopharma?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Arbutus Biopharma?
      To buy shares of GB:0SGC, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.